HK Stock Market Move | GENSCRIPT B-1K (01548) Rises Over 5%; Institutions Bullish on AIDD Driving Strong Growth in Company's Life Sciences Business

GENSCRIPT B-1K (01548) rose over 5%, up 5.13% as of press time to HK$31.94, with turnover of HK$493 million. On the news front, Huatai released a research report stating that GENSCRIPT B-1K recently held its 2026 Investor Day, sharing insights on industry opportunities brought by AIDD, technology platform development, business layout, and long-term growth strategy. The bank is bullish on China's AI-driven drug discovery (AIDD) driving strong growth in the company's life sciences business, while other businesses develop in an orderly manner. The bank raised its profit forecasts for the company for 2026 to 2028 to US$24 million, US$394 million, and US$586 million, corresponding to earnings per share of 1 US cent, 19 US cents, and 28 US cents; of which 2026 marks a turnaround to profitability, with year-on-year growth rates of 1,565% and 49% for 2027 and 2028 respectively. The report noted that as AI accelerates molecular design and candidate generation, experimental validation and data generation are becoming bottlenecks and key links in value realization, and GenScript is benefiting from AIDD wet-lab outsourcing demand. The company expects the compound annual growth rate of its life sciences AIDD serviceable addressable market to reach 50% to 80% over the next three years; AIDD will drive wet-lab demand from four aspects: more customers, faster iteration cycles, higher validation throughput, and deeper wet-lab requirements.